Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1033 publications
Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.
Journal: JAMA network open
Published: October 13, 2025
Missed Doses, Missed Opportunities: Readmission Due to GLP-1RA Interruption Inspires Algorithms to Improve Reinitiation of Therapy at Discharge.
Journal: Hospital pharmacy
Published: September 29, 2025
GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024.
Journal: NCHS data brief
Published: September 29, 2025
Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists.
Journal: JAMA surgery
Published: September 17, 2025
Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases.
Journal: Nano letters
Published: September 08, 2025
Scoping Review-Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions.
Journal: Journal of diabetes science and technology
Published: September 02, 2025
Trends in glucagon-like peptide 1 receptor agonist prescribing patterns.
Journal: The American journal of managed care
Published: August 19, 2025
Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.
Journal: Annals of internal medicine
Published: August 18, 2025
Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review.
Journal: Cureus
Published: August 13, 2025
Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: August 07, 2025
Generalizability of glucagon-like peptide 1 receptor agonist clinical trial results to product labeling and the real world.
Journal: Annals of the New York Academy of Sciences
Published: August 05, 2025
Web Exclusive. Annals On Call - Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control Is Inadequate With Dulaglutide.
Journal: Annals of internal medicine
Published: August 04, 2025
Last Updated: 10/31/2025